Our Pipeline
Focused innovation with STAT3 as our anchor target, transforming 'undruggable' challenges into breakthrough therapies for fibrosis and oncology.
TTI-101: Our Lead Candidate
An oral small molecule inhibitor selectively targeting the STAT3 SH2 domain
Mechanism of Action
TTI-101 is designed to selectively bind to the SH2 domain of STAT3, blocking pathological signaling that drives disease progression in fibrosis and cancer while maintaining minimal off-target toxicity.
Selective Targeting
Precisely binds to the STAT3 SH2 domain with high specificity, avoiding off-target effects.
Disrupts Pathological Signaling
Prevents STAT3 dimerization and nuclear translocation, blocking transcription of disease-promoting genes.
Demonstrated Efficacy
Shown robust activity in preclinical models of IPF and HCC, with promising early clinical data.
STAT3 Signaling Pathway
The STAT3 pathway plays a crucial role in fibrosis, inflammation, and tumor progression. TTI-101 specifically targets the SH2 domain, blocking the pathological effects while preserving normal cellular function.
Clinical Trials
Our lead candidate TTI-101 is being evaluated in two key clinical trials with near-term catalysts
RENEW-IPF Trial
Evaluating TTI-101 in patients with Idiopathic Pulmonary Fibrosis, a progressive lung disease with high unmet need.
RECLAIM-HCC Trial
Evaluating TTI-101 as monotherapy and in combination with standard-of-care in advanced Hepatocellular Carcinoma.
Pipeline Overview
Our development programs span multiple indications with a focus on fibrosis and oncology
Partnering Opportunities
We are seeking strategic partnerships to accelerate our pipeline development and expand the therapeutic potential of our proprietary STAT3 platform.
Co-development partnerships
Licensing opportunities
Research collaborations
Strategic investments